Research programme: antiresorptive bone cancer therapy - AuxerisAlternative Names: AUX-201; AUX-202
Latest Information Update: 26 Mar 2007
At a glance
- Originator Auxeris Therapeutics (CEASED)
- Mechanism of Action Osteoclast inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bone cancer
Most Recent Events
- 27 Aug 2003 Preclinical trials in Bone cancer in USA (unspecified route)